IL-1β inhibition in cardiovascular complications associated to diabetes mellitus

Frontiers in Pharmacology

Volumn 8, Issue JUN, 2017, Pages

  Peiró, Concepción ^a,b   Lorenzo, óscar ^a,c   Carraro, Raffaele ^a,d   Sánchez Ferrer, Carlos F ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Cardiovascular complications; Diabetes; Inflammation; Interleukin 1 inhibitors; Interleukin 1

Indexed keywords

ANAKINRA; CANAKINUMAB; GEVOKIZUMAB; INFLAMMASOME; INTERLEUKIN 1BETA; PLACEBO; RILONACEPT;

AGING; APOPTOSIS; ATHEROSCLEROSIS; AUTOINFLAMMATORY DISEASE; AUTOPHAGY; CARDIOVASCULAR DISEASE; CARDITIS; CINCA SYNDROME; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; DIABETIC RETINOPATHY; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PHARMACOLOGICAL BLOCKING; PYODERMA GANGRENOSUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SCHNITZLER SYNDROME; SECONDARY PREVENTION; UVEITIS; VASCULITIS;

EID: 85020772837     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00363     Document Type: Review

References (124)

1. Abbate, A., Salloum, F. N., Vecile, E., Das, A., Hoke, N. N., Straino, S., et al. (2008). Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 117, 2670-2683. doi: 10.1161/CIRCULATIONAHA.107.740233
2. Abbate, A., Van Tassell, B. W., Seropian, I. M., Toldo, S., Robati, R., Varma, A., et al. (2010). Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur. J. Heart Fail. 12, 319-322. doi: 10.1093/eurjhf/hfq017
3. Amin, A., Choi, S. K., Galan, M., Kassan, M., Partyka, M., Kadowitz, P., et al. (2012). Chronic inhibition of endoplasmic reticulum stress and inflammation prevents ischaemia-induced vascular pathology in type II diabetic mice. J. Pathol. 227, 165-174. doi: 10.1002/path.3960
4. Angulo, J., Rodríguez-Mañas, L., Peiró, C., Neira, M., Marín, J., and Sánchez-Ferrer, C. F. (1998). Impairment of nitric oxide-mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats. Naunyn Schmiedebergs Arch. Pharmacol. 358, 529-537
5. Ares-Carrasco, S., Picatoste, B., Benito-Martín, A., Zubiri, I., Sanz, A. B., Sánchez-Niño, M. D., et al. (2009). Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. Am. J. Physiol. Heart Circ. Physiol. 297, H2109-H2119. doi: 10.1152/ajpheart.00157.2009
6. Asakawa, H., Miyagawa, J., Hanafusa, T., Kuwajima, M., and Matsuzawa, Y. (1997). High glucose and hyperosmolarity increase secretion of interleukin-1 beta in cultured human aortic endothelial cells. J. Diab. Compl. 11, 176-179. doi: 10.1016/S1056-8727(97)00004-4
7. Azcutia, V., Abu-Taha, M., Romacho, T., Vázquez-Bella, M., Matesanz, N., Luscinskas, F. W., et al. (2010). Inflammation determines the pro-adhesive properties of high extracellular d-glucose in human endothelial cells in vitro and rat microvessels in vivo. PLoS ONE 5:e10091. doi: 10.1371/journal.pone.0010091
8. Ballak, D. B., Stienstra, R., Tack, C. J., Dinarello, C. A., and van Diepen, J. A. (2015). IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. Cytokine 75, 280-290. doi: 10.1016/j.cyto.2015.05.005
9. Barton, M. (2010). Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis. Pflugers Arch. 460, 825-837. doi: 10.1007/s00424-010-0860-y
10. Beetz, N., Rommel, C., Schnick, T., Neumann, E., Lother, A., Monroy-Ordonez, E. B., et al. (2016). Ablation of biglycan attenuates cardiac hypertrophy and fibrosis after left ventricular pressure overload. J. Mol. Cell. Cardiol. 101, 145-155. doi: 10.1016/j.yjmcc.2016.10.011
11. Bergsbaken, T., Fink, S. L., and Cookson, B. T. (2009). Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol. 7, 99-109. doi: 10.1038/nrmicro2070
12. Brodsky, S. V., Gealekman, O., Chen, J., Zhang, F., Togashi, N., Crabtree, M., et al. (2004). Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circ Res. 94, 377-384. doi: 10.1161/01.RES.0000111802.09964.EF
13. Bujak, M., Dobaczewski, M., Chatila, K., Mendoza, L. H., Li, N., Reddy, A., etal. (2008). Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am. J. Pathol. 173, 57-67. doi: 10.2353/ajpath.2008.070974
14. Bujak, M., and Frangogiannis, N. G. (2009). The role of Interleukin-1 in the pathogenesis of heart disease. Arch. Immunol. Ther. Exp. 57, 165-176. doi: 10.1007/s00005-009-0024-y
15. Calver, A., Collier, J., and Vallance, P. (1992). Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J. Clin. Invest. 90, 2548-2554. doi: 10.1172/JCI116149
16. Cavelti-Weder, C., Timper, K., Seelig, E., Keller, C., Osranek, M., Lässing, U., et al. (2016). Development of an interleukin-1β vaccine in patients with type 2 Diabetes. Mol. Ther. 24, 1003-1012. doi: 10.1038/mt.2015.227
17. Chakraborty, A., Tannenbaum, S., Rordorf, C., Lowe, P. J., Floch, D., Gram, H., et al. (2012). Pharmacokinetic and pharmacodynamics properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin. Pharmacokinet. 51, e1-e18. doi: 10.2165/11599820-000000000-00000
18. Chamberlain, J., Evans, D., King, A., Dewberry, R., Dower, S., Crossman, D., et al. (2006). Interleukin-1 beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am. J. Pathol. 168, 1396-1403. doi: 10.2353/ajpath.2006.051054
19. Chen, J., Brodsky, S. V., Goligorsky, D. M., Hampel, D. J., Li, H., Gross, S. S., et al. (2002). Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ. Res. 90, 1290-1298. doi: 10.1161/01.RES.0000022161.42655.98
20. Chen, N. X., and Moe, S. M. (2003). Arterial calcification in diabetes. Curr. Diab. Rep. 3, 28-32. doi: 10.1007/s11892-003-0049-2
21. Chi, H., Messas, E., Levine, R. A., Graves, D. T., and Amar, S. (2004). Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation 110, 1678-1685. doi: 10.1161/01.CIR.0000142085.39015.31
22. Choudhury, R. P., Birks, J. S., Mani, V., Biasiolli, L., Robson, M. D., L'Allier, P. L., et al. (2016). Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance. J. Am. Coll. Cardiol. 68, 1769-1780. doi: 10.1016/j.jacc.2016.07.768
23. Dai, R. P., Dheen, S. T., He, B. P., and Tay, S. S. W. (2004). Differential expression of cytokines in the rat heart in response to sustained volume overload. Eur. J. Heart Fail. 6, 693-703. doi: 10.1016/j.ejheart.2003.11.014
24. Dasu, M. R., Devaraj, S., and Jialal, I. (2007). High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am. J. Physiol. Endocrinol. Metab. 293, E337-E346. doi: 10.1152/ajpendo.00718.2006
25. Dinarello, C. A. (2014). An expanding role for interleukin-1 blockade from gout to cancer. Mol. Med. 20(Suppl. 1), S43-S58. doi: 10.2119/molmed.2014.00232
26. Dinarello, C. A., Donath, M. Y., and Mandrup-Poulsen, T. (2010). Role of IL-1beta in type 2 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 17, 314-321. doi: 10.1097/MED.0b013e32833bf6dc
27. Dinarello, C. A., Simon, A., and van der Meer, J. W. (2012). Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug. Discov. 11, 633-652. doi: 10.1038/nrd3800
28. Donath, M. Y., and Shoelson, S. E. (2011). Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11, 98-107. doi: 10.1038/nri2925
29. Durante, W., Sen, A. K., and Sunahara, F. A. (1988). Impairment of endothelium-dependent relaxation in aortae from spontaneously diabetic rats. Br. J. Pharmacol. 94, 463-468. doi: 10.1111/j.1476-5381.1988.tb11548.x
30. Erusalimsky, J. D. (2009). Vascular endothelial senescence: from mechanisms to pathophysiology. J. Appl. Physiol. 106, 326-332. doi: 10.1152/japplphysiol.91353.2008
31. Fang, L., Moore, X.-L., Dart, A. M., and Wang, L.-M. (2015). Systemic inflammatory response following acute myocardial infarction. J. Geriatr. Cardiol. 12, 305-312. doi: 10.11909/j.issn.1671-5411.2015.03.020
32. Félétou, M., and Vanhoutte, P. M. (2006). Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am. J. Physiol. Heart Circ. Physiol. 291, H985-H1002
33. Fisman, E. Z., Adler, Y., and Tenenbaum, A. (2008). Biomarkers in cardiovascular diabetology: interleukins and matrixins. Adv. Cardiol. 45, 44-64. doi: 10.1159/0000115187
34. Franchi, L., Eigenbrod, T., Muñoz-Planillo, R., and Nuñez, G. (2009). The inflammasome: a caspase-1 activation platform regulating immune responses and disease pathogenesis. Nat. Immunol. 10:241. doi: 10.1038/ni.1703
35. Frangogiannis, N. G., Ren, G., Dewald, O., Zymek, P., Haudek, S., Koerting, A., et al. (2005). Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation 111, 2935-2942. doi: 10.1161/CIRCULATIONAHA.104.510354
36. Frostegård, J. (2013). Immune mechanisms in atherosclerosis, especially in diabetes type 2. Front. Endocrinol. 4:162. doi: 10.3389/fendo.2013.00162
37. Frostegård, J., Ulfgren, A. K., Nyberg, P., Hedin, U., Swedenborg, J., Andersson, U., et al. (1999). Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 145, 33-43. doi: 10.1016/S0021-9150(99)00011-8
38. Fuentes-Antras, J., Ioan, A. M., Tunon, J., Egido, J., and Lorenzo, O. (2014). Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-Associated inflammation. Int. J. Endocrinol. 2014:847827. doi: 10.1155/2014/847827
39. Goldberg, R. B. (2009). Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin. Endocrinol. Metab. 94, 3171-3182. doi: 10.1210/jc.2008-2534
40. Gordon, J. W., Shaw, J. A., and Kirshenbaum, L. A. (2011). Multiple facets of NF-κB in the heart to be or not to NF-κB. Circ. Res. 108, 1122-1132. doi: 10.1161/CIRCRESAHA.110.226928
41. Gray, S. P., Di Marco, E., Okabe, J., Szyndralewiez, C., Heitz, F., Montezano, A. C., et al. (2013). NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 127, 1888-1902. doi: 10.1161/CIRCULATIONAHA.112.132159
42. Hedayat, M., Mahmoudi, M. J., Rose, N. R., and Rezaei, N. (2010). Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail. Rev. 15, 543-562. doi: 10.1007/s10741-010-9168-4
43. Hensen, J., Howard, C. P., Walter, V., and Thuren, T. (2013). Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab. 39, 524-531. doi: 10.1016/j.diabet.2013.07.003
44. Herder, C., Dalmas, E., Böni-Schnetzler, M., and Donath, M. E. (2015). The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol. Metab. 26, 551-563. doi: 10.1016/j.tem.2015.08.001
45. Herskowitz, A., Choi, S., Ansari, A. A., and Wesselingh, S. (1995). Cytokine mRNA expression in postischemic/reperfused myocardium. Am. J. Pathol. 146, 419-428
46. Higashikuni, Y., Tanaka, K., Kato, M., Nureki, O., Hirata, Y., Nagai, R., et al. (2013). Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1β upregulation via nuclear factor κB activation. J. Am. Heart Assoc. 2:e000267. doi: 10.1161/JAHA.113.000267
47. Hingorani, A. D., Cross, J., Kharbanda, R. K., Mullen, M. J., Bhagat, K., Taylor, M., et al. (2000). Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 102, 994-999. doi: 10.1161/01.CIR.102.9.994
48. Howard, C., Noe, A., Skerjanec, A., Holzhauer, B., Wernsing, M., Ligueros-Saylan, M., et al. (2014). Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovasc. Diabetol. 13:94. doi: 10.1186/1475-2840-13-94
49. Hu, Z.-C., Chen, Y.-D., and Ren, Y.-H. (2011). Methylprednisolone improves microcirculation in streptozotocin-induced diabetic rats after myocardial ischemia/reperfusion. Chin. Med. J. 124, 923-929. doi: 10.3760/cma.j.issn.0366-6999.2011.06.022
50. Isoda, K., Sawada, S., Ishigami, N., Matsuki, T., Miyazaki, K., Kusuhara, M., et al. (2004). Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 24, 1068-1073. doi: 10.1161/01.ATV.0000127025.48140.a3
51. Jesus, A. A., and Goldbach-Mansky, R. (2014). IL-1 blockade in autoinflammatory syndromes. Annu. Rev. Med. 65, 223-244. doi: 10.1146/annurev-med-061512-150641
52. Jiménez-Altayó, F., Briones, A. M., Giraldo, J., Planas, A. M., Salaices, M., and Vila, E. (2006). Increased superoxide anion production by interleukin-1beta impairs nitric oxide-mediated relaxation in resistance arteries. J. Pharmacol. Exp. Ther. 316, 42-52. doi: 10.1124/jpet.105.088435
53. Johnstone, M. T., Creager, S. J., Scales, K. M., Cusco, J. A., Lee, B. K., and Creager, M. A. (1993). Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88, 2510-2516. doi: 10.1161/01.CIR.88.6.2510
54. Kharbanda, R. K., Walton, B., Allen, M., Klein, N., Hingorani, A. D., MacAllister, R. J., et al. (2002). Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation 105, 2600-2604. doi: 10.1161/01.CIR.0000017863.52347.6C
55. Krishnan, S. M., Sobey, C. G., Latz, E., Mansell, A., and Drummond, G. R. (2014). IL-1β and IL-18: inflammatory markers or mediators of hypertension? Br. J. Pharmacol. 171, 5589-5602. doi: 10.1111/bph.12876
56. Kullenberg, T., Löfqvist, M., Leinonen, M., Goldbach-Mansky, R., and Olivecrona, H. (2016). Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology 55, 1499-1506. doi: 10.1093/rheumatology/kew208
57. Lafuente, N., Matesanz, N., Azcutia, V., Romacho, T., Nevado, J., Rodríguez-Mañas, L., et al. (2008). The deleterious effect of high concentrations of D-glucose requires pro-inflammatory preconditioning. J. Hypertens 26, 478-485. doi: 10.1097/HJH.0b013e3282f331fb
58. Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., and Mandrup-Poulsen, T. (2009). Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32, 1663-1668. doi: 10.2337/dc09-0533
59. Larsen, C. M., Faulenbach, M., Vaag, A., Volund, A., Ehses, J. A., Seifert, B., et al. (2007). Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526. doi: 10.1056/NEJMoa065213
60. Laugesen, E., Høyem, P., Stausbøl-Grøn, B., Mikkelsen, A., Thrysøe, S., Erlandsen, M., et al. (2013). Carotid-femoral pulse wave velocity is associated with cerebral white matter lesions in type 2 diabetes. Diabetes Care 36, 722-728. doi: 10.2337/dc12-0942
61. Lencel, P., Delplace, S., Pilet, P., Leterme, D., Miellot, F., Sourice, S., et al. (2011). Cell-specific effects of TNF-a and IL-1β on alkaline phosphatase: implication for syndesmophyte formation and vascular calcification. Lab. Invest. 9, k1434-1442. doi: 10.1038/labinvest.2011.83
62. Lenna, S., Han, R., and Trojanowska, M. (2014). ER stress and endothelial dysfunction. IUBMB Life 66, 530-537. doi: 10.1002/iub.1292
63. Li, T.-S., Takahashi, M., Suzuki, R., Kobayashi, T., Ito, H., Mikamo, A., et al. (2006). Pravastatin improves remodeling and cardiac function after myocardial infarction by an antiinflammatory mechanism rather than by the induction of angiogenesis. Ann. Thorac. Surg. 81, 2217-2225. doi: 10.1016/j.athoracsur.2005.12.065
64. Liu, Y., Biarnés Costa, M., and Gerhardinger, C. (2012). IL-1β is upregulated in the diabetic retina and retinal vessels: cell-specific effect of high glucose and IL-1β autostimulation. PLoS ONE 7:e36949. doi: 10.1371/journal.pone.0036949
65. Liu, Z., Lerman, L. O., Tang, H., Barber, C., Wan, L., Hui, M. M., et al. (2014). Inflammation imaging of atherosclerosis in Apo-E-deficient mice using a 99mTc-labeled dual-domain cytokine ligand. Nucl. Med. Biol. 41, 785-792. doi: 10.1016/j.nucmedbio.2014.08.004
66. Liu, Z., Zhao, N., Zhu, H., Zhu, S., Pan, S., Xu, J., et al. (2015). Circulating interleukin-1β promotes endoplasmic reticulum stress-induced myocytes apoptosis in diabetic cardiomyopathy via interleukin-1 receptor-associated kinase-2. Cardiovasc. Diabetol. 14:125. doi: 10.1186/s12933-015-0288-y
67. Luo, B., Li, B., Wang, W., Liu, X., Xia, Y., Zhang, C., et al. (2014a). NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS ONE 9:e104771. doi: 10.1371/journal.pone.0104771
68. Luo, B., Li, B., Wang, W., Liu, X., Liu, X., Xia, Y., et al. (2014b). Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc. Drugs Ther. 28, 33-43. doi: 10.1007/s10557-013-6498-1
69. Maedler, K., Sergeev, P., Ehses, J. A., Mathe, Z., Bosco, D., Berney, T., et al. (2004). Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc. Natl. Acad. Sci. U.S.A. 101, 8138-8143. doi: 10.1073/pnas.0305683101
70. McTiernan, C. F., Lemster, B. H., Frye, C., Brooks, S., Combes, A., and Feldman, A. M. (1997). Interleukin-1β inhibits phospholamban gene expression in cultured cardiomyocytes. Circ. Res. 81, 493-503. doi: 10.1161/01.RES.81.4.493
71. Merhi-Soussi, F., Kwak, B. R., Magne, D., Chadjichristos, C., Berti, M., Pelli, G., et al. (2005). Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc. Res. 66, 583-593. doi: 10.1016/j.cardiores.2005.01.008
72. Minamino, T., and Komuro, I. (2007). Vascular cell senescence: contribution to aterosclerosis. Circ. Res. 100, 15-26. doi: 10.1161/01.RES.0000256837.40544.4a
73. Minamino, T., Miyauchi, H., Yoshida, T., Ishida, Y., Yoshida, H., and Komuro, I. (2002). Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 105, 1541-1544. doi: 10.1161/01.CIR.0000013836.85741.17
74. Monnerat, G., Alarcón, M. L., Vasconcellos, L. R., Hochman-Mendez, C., Brasil, G., Bassani, R. A., et al. (2016). Macrophage-dependent IL-1β production induces cardiac arrhythmias in diabetic mice. Nat. Commun. 7:13344. doi: 10.1038/ncomms13344
75. Mooradian, A. D., Reed, R. L., Meredith, K. E., and Scuderi, P. (1991). Serum levels of tumor necrosis factor and IL-1 alpha and IL-1 beta in diabetic patients. Diabetes Care 14, 63-65. doi: 10.2337/diacare.14.1.63
76. Niu, J., Gilliland, M. G. F., Jin, Z., Kolattukudy, P. E., and Hoffman, W. H. (2014). MCP-1and IL-1β expression in the myocardia of two young patients with Type 1 diabetes mellitus and fatal diabetic ketoacidosis. Exp. Mol. Pathol. 96, 71-79. doi: 10.1016/j.yexmp.2013.11.001
77. Noe, A., Howard, C., Thuren, T., Taylor, A., and Skerjanec, A. (2014). Pharmacokinetic and pharmacodynamic characteristics of single-dose canakinumab in patients with type 2 diabetes mellitus. Clin. Ther. 36, 1625-1637. doi: 10.1016/j.clinthera.2014.08.004
78. Oddis, C. V., and Finkel, M. S. (1995). Cytokine-stimulated nitric oxide production inhibits mitochondrial activity in cardiac myocytes. Biochem. Biophys. Res. Commun. 213, 1002-1009. doi: 10.1006/bbrc.1995.2228
79. Oka, T., Hikoso, S., Yamaguchi, O., Taneike, M., Takeda, T., Tamai, T., et al. (2012). Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485, 251-255. doi: 10.1038/nature10992
80. Olukman, M., Orhan, C. E., Celenk, F. G., and Ulker, S. (2010). Apocynin restores endothelial dysfunction in streptozotocin diabetic rats through regulation of nitric oxide synthase and NADPH oxidase expressions. J. Diabetes Complications 24, 415-423. doi: 10.1016/j.jdiacomp.2010.02.001
81. Palmer, J. N., Hartogensis, W. E., Patten, M., Fortuin, F. D., and Long, C. S. (1995). Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J. Clin. Invest. 95, 2555-2564. doi: 10.1172/JCI117956
82. Palomo, J., Dietrich, D., Martin, P., Palmer, G., and Gabay, C. (2015). The interleukin (IL)-1 cytokine family-Balance between agonists and antagonists in inflammatory diseases. Cytokine 76, 25-37. doi: 10.1016/j.cyto.2015.06.017
83. Patel, J. I., Saleh, G. M., Hykin, P. G., Gregor, Z. J., and Cree, I. A. (2008). Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy. Eye 22, 223-228. doi: 10.1038/sj.eye.6702584
84. Peiró, C., Romacho, T., Azcutia, V., Villalobos, L., Fernández, E., Bolaños, J. P., et al. (2016). Inflammation, glucose, and vascular cell damage: the role of the pentose phosphate pathway. Cardiovasc. Diabetol. 15:82. doi: 10.1186/s12933-016-0397-2
85. Pereira, M. M., Santos, T. P., Aras, R., Couto, R. D., Sousa Atta, M. L., and Atta, A. M. (2014). Serum levels of cytokines and chemokines associated with cardiovascular disease in Brazilian patients treated with statins for dyslipidemia. Int. Immunopharmacol. 18, 66-70. doi: 10.1016/j.intimp.2013.11.003
86. Pessolano, L. G. Jr., Sullivan, C. P., Seidl, S. E., Rich, C. B., Liscum, L., Stone, P. J., et al. (2012). Trafficking of endogenous smooth muscle cell cholesterol: a role for serum amyloid A and interleukin-1β. Arterioscler. Thromb. Vasc. Biol. 32, 2741-2750. doi: 10.1161/ATVBAHA.112.300243
87. Pollack, R. M., Donath, M. Y., LeRoith, D., and Leibowitz, G. (2016). Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care 39(Suppl. 2), S244-S252. doi: 10.2337/dcS15-3015
88. Prabhu, S. D., and Frangogiannis, N. G. (2016). The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ. Res. 119, 91-112. doi: 10.1161/CIRCRESAHA.116.303577
89. Raines, E. W., and Ferri, N. (2005). Thematic review series: The immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J. Lipid Res. 46, 1081-1092. doi: 10.1194/jlr.R500004-JLR200
90. Ridker, P. M., Howard, C. P., Walter, V., Everett, B., Libby, P., Hensen, J., et al. (2012). CANTOS pilot investigative group. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126, 2739-2748. doi: 10.1161/CIRCULATIONAHA.112.122556
91. Ridker, P. M., Thuren, T., Zalewski, A., and Libby, P. (2011). Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597-605. doi: 10.1016/j.ahj.2011.06.012
92. Rissanen, A., Howard, C. P., Botha, J., and Thuren, T. (2012). Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes. Metab. 14, 1088-1096
93. Rodríguez-Mañas, L., Angulo, J., Vallejo, S., Peiró, C., Sánchez-Ferrer, A., Cercas, E., et al. (2003a). Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature. Diabetologia 46, 556-566
94. Rodríguez-Mañas, L., López-Dóriga, P., Petidier, R., Neira, M., Solís, J., Pavón, I., et al. (2003b). Effect of glycaemic control on the vascular nitric oxide system in patients with type 1 diabetes. J. Hypertens. 21, 1137-1143
95. Sandanger,Ø., Ranheim, T., Vinge, L.-E., Bliksøen, M., Alfsnes, K., Finsen, A. V., et al. (2013). The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc. Res. 99, 164-174. doi: 10.1093/cvr/cvt091
96. Schreiber, B. M. (2002). Serum amyloid A; in search of function. Amyloid 9, 276-278. doi: 10.3109/13506120209114107
97. Schulz, R., Panas, D. L., Catena, R., Moncada, S., Olley, P. M., and Lopaschuk, G. D. (1995). The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha. Br. J. Pharmacol. 114, 27-34. doi: 10.1111/j.1476-5381.1995.tb14901.x
98. Shakhov, A. N., Collart, M. A., Vassalli, P., Nedospasov, S. A., and Jongeneel, C. V. (1990). Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J. Exp. Med. 171, 35-47. doi: 10.1084/jem.171.1.35
99. Shashkin, P. N., Jain, N., Miller, Y. I., Rissing, B. A., Huo, Y., Keller, S. R., et al. (2006). Insulin and glucose play a role in foam cell formation and function. Cardiovasc. Diabetol. 5:13
100. Shikama, Y., Aki, N., Hata, A., Nishimura, M., Oyadomari, S., and Funaki, M. (2015). Palmitate-stimulated monocytes induce adhesion molecule expression in endothelial cells via IL-1 signaling pathway. J. Cell Physiol. 230, 732-742. doi: 10.1002/jcp.24797
101. Shinde, A. V., and Frangogiannis, N. G. (2014). Fibroblasts in myocardial infarction: a role in inflammation and repair. J. Mol. Cell. Cardiol. 70, 74-82. doi: 10.1016/j.yjmcc.2013.11.015
102. Singla, D. K., Singla, R., and Wang, J. (2016). BMP-7 treatment increases M2 macrophage differentiation and reduces inflammation and plaque formation in Apo E-/-mice. PLoS ONE 11:e0147897. doi: 10.1371/journal.pone.0147897
103. Siwik, D. A., Chang, D. L., and Colucci, W. S. (2000). Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ. Res. 86, 1259-1265. doi: 10.1161/01.RES.86.12.1259
104. Siwik, D. A., and Colucci, W. S. (2004). Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail. Rev. 9, 43-51. doi: 10.1023/B:HREV.0000011393.40674.13
105. Sloan-Lancaster, J., Abu-Raddad, E., Polzer, J., Miller, J. W., Scherer, J. C., De Gaetano, A., et al. (2013). Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care 36, 2239-2246. doi: 10.2337/dc12-1835
106. Sloboda, N., Fève, B., Thornton, S. N., Nzietchueng, R., Regnault, V., Simon, G., et al. (2012). Fatty acids impair endothelium-dependent vasorelaxation: a link between obesity and arterial stiffness in very old Zucker rats. J. Gerontol. A Biol. Med. Sci. 67, 927-938. doi: 10.1093/gerona/glr236
107. Sowers, J. R. (2013). Diabetes mellitus and vascular disease. Hypertension 61, 943-947. doi: 10.1161/HYPERTENSIONAHA.111.00612
108. Sprague, A. H., and Khalil, R. A. (2009). Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol. 78, 539-552. doi: 10.1016/j.bcp.2009.04.029
109. Stahel, M., Becker, M., Graf, N., and Michels, S. (2016). Systemic interleukin 1β inhibition in proliferative diabetic retinopathy: a prospective open-label study using canakinumab. Retina 36, 385-391. doi: 10.1097/IAE.0000000000000701
110. Stein, B., Frank, P., Schmitz, W., Scholz, H., and Thoenes, M. (1996). Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J. Mol. Cell. Cardiol. 28, 1631-1639. doi: 10.1006/jmcc.1996.0153
111. Sumpter, K. M., Adhikari, S., Grishman, E. K., and White, P. C. (2011). Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes. Pediatr. Diabetes 7, 656-667. doi: 10.1111/j.1399-5448.2011.00761.x
112. Tatsumi, T., Matoba, S., Kawahara, A., Keira, N., Shiraishi, J., Akashi, K., et al. (2000). Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J. Am. Coll. Cardiol. 35, 1338-1346. doi: 10.1016/S0735-1097(00)00526-X
113. The Interleukin 1 Genetics Consortium (2015). Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 3, 243-253. doi: 10.1016/S2213-8587(15)00034-0
114. Toldo, S., Mezzaroma, E., Bressi, E., Marchetti, C., Carbone, S., Sonnino, C., et al. (2014). Interleukin-1β blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse. J. Cardiovasc. Pharmacol. 64, 1-6. doi: 10.1097/FJC.0000000000000106
115. Tschöpe, C., Walther, T., Escher, F., Spillmann, F., Du, J., Altmann, C., et al. (2005). Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J. 19, 2057-2059. doi: 10.1096/fj.05-4095fje
116. Vallejo, S., Palacios, E., Romacho, T., Villalobos, L., Peiró, C., and Sánchez-Ferrer, C. F. (2014). The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats. Cardiovasc. Diabetol. 13:158. doi: 10.1186/s12933-014-0158-z
117. van Asseldonk, E. J., Stienstra, R., Koenen, T. B., Joosten, L. A., Netea, M. G., and Tack, C. J. (2011). Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 2011, 2119-2126. doi: 10.1210/jc.2010-2992
118. Varma, A., Das, A., Hoke, N. N., Durrant, D. E., Salloum, F. N., and Kukreja, R. C. (2012). Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. PLoS ONE. 7:e45243. doi: 10.1371/journal.pone.0045243
119. Vila, E., and Salaices, M. (2005). Cytokines and vascular reactivity in resistance arteries. Am. J. Physiol. Heart Circ. Physiol. 288, H1016-H1021
120. Westermann, D., Van Linthout, S., Dhayat, S., Dhayat, N., Schmidt, A., Noutsias, M., et al. (2007). Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res. Cardiol. 102, 500-507. doi: 10.1007/s00395-007-0673-0
121. Wimalasundera, R., Fexby, S., Regan, L., Thom, S. A., and Hughes, A. D. (2003). Effect of tumour necrosis factor-alpha and interleukin 1beta on endothelium-dependent relaxation in rat mesenteric resistance arteries in vitro. Br. J. Pharmacol. 138, 1285-1294. doi: 10.1038/sj.bjp.0705168
122. Xie, Z., Singh, M., and Singh, K. (2004). Differential regulation of matrix metalloproteinase-2 and-9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1beta. J. Biol. Chem. 279, 39513-39519. doi: 10.1074/jbc.M405844200
123. Yazar, M., Deger, Y., and Yur, F. (2011). Serum cytokine and vitamine E levels in experimental diabetic rats. J. Anim. Vet. Adv. 10, 622-626. doi: 10.3923/javaa.2011.622.626
124. Zhu, D., Mackenzie, N. C., Farquharson, C., and Macrae, V. E. (2012). Mechanisms and clinical consequences of vascular calcification. Front. Endocrinol. 3:95. doi: 10.3389/fendo.2012.00095